Sign in

You're signed outSign in or to get full access.

UT

Unicycive Therapeutics, Inc. (UNCY)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 diluted EPS was $(0.33), a significant beat versus Wall Street consensus of $(0.53)*; net loss was $6.01M as total operating expenses rose due to higher G&A while R&D declined modestly year over year .
  • Cash and cash equivalents were $42.7M with stated cash runway into 2027, strengthening balance sheet flexibility for regulatory and potential launch activities .
  • Management plans to resubmit the OLC NDA by year-end following a Type A FDA meeting; the single deficiency was limited to a third-party manufacturing vendor with no additional preclinical/clinical/safety issues, and EU inspectors recently found no deficiencies at the vendor; potential new PDUFA date in 1H 2026 .
  • New ASN Kidney Week analysis showed OLC reduced pill burden by 7x in pill volume and 2x in pill count versus pretrial binders, reinforcing differentiation and potential adherence benefits—an important commercial narrative if approved .
  • Stock reaction catalysts: near-term NDA resubmission and probability of a 1H 2026 PDUFA date; medium-term clinical differentiation on pill burden; overhang from CRL in June and ongoing class-action headlines could modulate sentiment until regulatory clarity improves .

Values with an asterisk (*) are retrieved from S&P Global.

What Went Well and What Went Wrong

What Went Well

  • “We are poised to resubmit the NDA for OLC by the end of the year, following positive discussions with the FDA and our third-party manufacturing vendor.” — CEO Shalabh Gupta, M.D. .
  • “We are very encouraged about the potential for a swift resolution of the issue raised in our CRL and we believe we are now on track to resubmit our NDA before the end of the year.” — CEO Shalabh Gupta, M.D. .
  • OLC’s ASN data show material pill-burden reductions (7x pill volume; 2x pill count) versus pretrial therapy, bolstering the product’s convenience/adherence story .
  • Cash runway into 2027 provides adequate funding to complete regulatory milestones and prepare for potential launch .

What Went Wrong

  • Net loss widened year over year to $6.01M from $4.10M, driven by higher G&A (+$1.17M) and lower other income (warrant liability fair value change), partially offset by lower R&D .
  • The FDA issued a Complete Response Letter (CRL) on June 30, 2025 related to cGMP deficiencies at a third-party subcontractor, deferring OLC’s prior June 28, 2025 PDUFA timeline .
  • Elevated legal/newsflow headwinds from multiple class-action announcements and law-firm press releases may create sentiment overhang until the NDA resubmission path resolves .

Financial Results

EPS vs Estimates (Post-Split Basis)

MetricQ1 2025Q2 2025Q3 2025
Primary EPS Consensus Mean ($)(0.62)*(0.70)*(0.53)*
Primary EPS Actual ($)(0.50)*(0.52)*(0.33)*

Values retrieved from S&P Global.*

Operating Expenses and Net Loss (YoY Comparison)

Metric ($USD Millions)Q3 2024Q3 2025
Research & Development3.045 2.964
General & Administrative3.206 4.378
Total Operating Expenses6.251 7.342
Other Income (Expense)2.155 1.331
Net Loss4.096 6.011
Diluted EPS ($)(0.46) (0.33)

Operating Expense Trend (Q/Q reference)

Metric ($USD Millions)Q1 2025Q3 2025
Research & Development2.171 2.964
General & Administrative5.818 4.378
Total Operating Expenses7.989 7.342

Liquidity and Balance Sheet Highlights

Metric ($USD Millions)Mar 31, 2025Jun 30, 2025Sep 30, 2025
Cash & Cash Equivalents19.769 ~20.7 42.695
Warrant Liability10.588 N/A9.147
Total Stockholders’ Equity11.271 N/A37.480

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
OLC NDA status2025NDA under FDA review; PDUFA target June 28, 2025 Resubmit NDA by year-end 2025 Deferred timeline (CRL-driven)
PDUFA timing2025/2026PDUFA June 28, 2025 Potential new PDUFA date in 1H 2026 Deferred to 1H 2026
Commercial launch2025/2026Anticipated launch in late 2025 (pre-CRL) Potential launch next year (2026), subject to approval Deferred (post-CRL)
Cash runwayMulti-yearInto 2026 (FY24 commentary) / into 2H 2026 (June 30 CRL PR) Into 2027 Raised runway

Earnings Call Themes & Trends

Note: No Q3 2025 earnings call transcript was available in our document catalog.

TopicPrevious Mentions (Q1 & Q2 2025)Current Period (Q3 2025)Trend
Regulatory pathway (OLC NDA)Q1: NDA under review; PDUFA 6/28/2025 . Q2: CRL citing cGMP deficiency at third-party subcontractor; plan Type A meeting .Type A meeting completed; resubmission by year-end; single deficiency limited to vendor; potential PDUFA in 1H 2026 .Moving toward resolution; timeline reset to 2026.
Clinical differentiation (pill burden)Q1: Patient-reported outcomes and surveys highlight adherence challenges .ASN open-label trial shows 7x pill volume and 2x pill count reduction vs pretrial binders .Strengthened product narrative; adherence advantages.
Commercial readinessQ1: Building functions, prescriber engagement, market access .“Well positioned” to prepare for potential launch next year post-approval .Continuing build with adjusted timing.
Liquidity runwayQ1: Cash $19.8M . Q2: ~$20.7M and runway into 2H 2026 .$42.7M cash; runway into 2027 .Improved funding flexibility.
Manufacturing vendorQ2: cGMP deficiency at third-party subcontractor .EU inspection of vendor reported no deficiencies; optimism on resolving CRL .Positive compliance trajectory.
Legal/overhangQ2/Q3: Multiple class-action press releases .Continued headlines in October .Persistent sentiment headwind until regulatory clarity.

Management Commentary

  • “With a continued commitment to advancing OLC, we are poised to resubmit the NDA for OLC by the end of the year, following positive discussions with the FDA and our third-party manufacturing vendor.” — Shalabh Gupta, M.D., CEO .
  • “We are very encouraged about the potential for a swift resolution of the issue raised in our CRL and we believe we are now on track to resubmit our NDA before the end of the year, which could lead to a PDUFA date in the first half of 2026.” — Shalabh Gupta, M.D., CEO .
  • “Treatment with our investigational phosphate binder OLC led to clinically meaningful and statistically significant reductions in pill burden in terms of both volume and number of pills...” — Shalabh Gupta, M.D., CEO (ASN announcement) .
  • “With a cash runway into 2027, we are well positioned to complete the regulatory approval process and prepare for the potential launch of OLC next year.” — Shalabh Gupta, M.D., CEO .

Q&A Highlights

  • No Q3 2025 earnings call transcript was found in our catalog; therefore, there are no Q&A themes or guidance clarifications to report for this quarter [ListDocuments, earnings-call-transcript returned none].

Estimates Context

  • Q3 EPS beat: Actual $(0.33) versus consensus $(0.53)*, a ~$0.20 upside. The beat likely reflects lower-than-expected net loss aided by R&D discipline and the quarter’s other income components (though other income declined year over year given warrant liability fair-value changes), and an adjusted share base post-reverse split aligning reported EPS with S&P post-split basis .
  • Prior quarters: Q2 actual EPS $(0.52)* vs $(0.70)* consensus (beat); Q1 actual EPS $(0.50)* vs $(0.62)* consensus (beat). The sequence of beats despite the CRL suggests opex/other income dynamics and share normalization mitigated losses more than modeled*.
  • Revenue: Consensus $0 across all three quarters*, consistent with the company’s pre-commercial status.

Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Bold beat on Q3 EPS vs consensus positions UNCY favorably into NDA resubmission; near-term catalysts include filing by year-end and potential PDUFA in 1H 2026 .
  • Liquidity improved materially to $42.7M with runway into 2027, supporting regulatory and pre-launch readiness without immediate financing pressure .
  • ASN pill-burden data reinforce OLC’s potential adherence advantage—commercial narrative likely to focus on fewer/smaller pills versus incumbents .
  • CRL scope limited to vendor cGMP compliance; EU inspection reported no deficiencies—risk now execution/timing rather than clinical profile; monitor 8-Ks/press on resubmission acceptance and PDUFA scheduling .
  • Near-term trading: Expect event-driven volatility around resubmission/newsflow; legal headline risk persists but is secondary to FDA timeline updates .
  • Medium-term thesis: If approved, differentiation on pill burden plus focused commercial build could drive uptake; key variables are label, payer access, and adherence outcomes in real-world settings .
  • Watch G&A trajectory post-launch prep; opex discipline and warrant liability impacts can swing EPS—model ranges should reflect these sensitivities .